Public Trust in Needle Exchange Programs: The Role of Information

This research is based on a telephone survey conducted in 2004 of San Diego residents (N = 400) who live in a neighborhood where a pilot needle exchange program was operating. The authors perform a multivariate analysis and find that level of information about the needle exchange program is positively related to level of trust in the program (p \u3c .01). The authors discuss the importance of public trust in the program as a means to increase the reciprocity and cooperation needed to continue the program’s operation. Although the program is now permanent, a small minority of vocal opponents still exists. Recommended Citation Baer, S. E. (2020, October 1-2). Public trust in needle exchange programs: The role of information [Poster presentation]. Walden University Research Conference 2020 (online). https://scholarworks.waldenu.edu/researchconference/2020/posters/24

Mass Transit Policy: Responding to COVID-19

Mass transit is vital to daily life in U.S. cities and many other cities throughout the world. Mass transit systems are vulnerable to pandemics like COVID-19 and other less serious threats. Post COVID-19 mass transit policy must be different than its predecessors if mass transit is to provide a reliable, sustainable, and equitable means of transportation. Future mass transit systems will be the outcome of public health, technological, economic, and political considerations. This paper provides an initial attempt to identify and discuss these four considerations as most relevant to the development of an equitable and efficient mass transit policy for rail and bus systems

Evaluation of an alternative ruxolitinib dosing regimen in patients with myelofibrosis: an open-label phase 2 study

Abstract Background Ruxolitinib improves splenomegaly and symptoms in patients with intermediate-2 or high-risk myelofibrosis; however, nearly half develop grade 3/4 anemia and/or thrombocytopenia, necessitating dose reductions and/or transfusions. We report findings from an open-label phase 2 study exploring a dose-escalation strategy aimed at preserving clinical benefit while reducing hematological adverse events early in ruxolitinib treatment. Methods Patients with myelofibrosis received ruxolitinib 10 mg twice daily (BID), with incremental increases of 5 mg BID at weeks 12 and 18 for lack of efficacy (maximum, 20 mg BID). Symptom severity was measured using the Myelofibrosis Symptom Assessment Form Total Symptom Score (MFSAF TSS). Results Forty-five patients were enrolled, 68.9% of whom had a Dynamic International Prognostic Scoring System score of 1 to 2 (i.e., intermediate-1 disease risk). Median percentage change in spleen volume from baseline to week 24 was − 17.3% (≥ 10% reduction achieved by 26 patients [57.8%]), with a clear dose response. Median percentage change in MFSAF TSS from baseline at week 24 was − 45.6%, also with a dose response. The most frequent treatment-emergent adverse events were anemia (26.7%), fatigue (22.2%), and arthralgias (20.0%). Grade 3/4 anemia (20.0%) and dose decreases due to anemia (11.1%) or thrombocytopenia (6.7%) were infrequent. Conclusions A dose-escalation approach may mitigate worsening anemia during early ruxolitinib therapy in some patients with myelofibrosis. Trial registration ClinicalTrials.gov identifier, NCT01445769 . Registered September 23, 2011.https://deepblue.lib.umich.edu/bitstream/2027.42/145195/1/13045_2018_Article_642.pd

Las enfermedades populares en la cultura española actual

Cabe suponer que cuando se goza de acceso universal a la sanidad, como sucede en la España contemporánea, la creencia en enfermedades populares termina desapareciendo. Sin embargo, una investigación de campo, desarrollada en el Suroeste de Andalucía en la primavera de 2004, indica que aún resta en la generalidad de la población un considerable conocimiento de un cierto número de enfermedades populares, y en concreto de la denominada «Mal de ojo». A partir de los datos obtenidos mediante un grupo de discusión con mujeres que curan estas enfermedades, la realización de una serie de entrevistas a personas o bien muy familiarizadas con el Mal de ojo, o bien profanas en esta enfermedad pero que creen en ella, y finalmente una revisión de materiales de archivo. Este artículo describe un modelo actual explicativo del Mal de ojo y propone algunas hipótesis sobre la pervivencia de la creencia en esta y otras enfermedades populares.It might be assumed that in a situation of universal access to biomedical health care, as is the case in contemporary Spain, folk illness beliefs would have vanished. Field research conducted in the spring of 2004 in Andalusia showed considerable knowledge in the general population about a number of folk illnesses, including mal de ojo (evil eye). Based on a focus group conducted with traditional healers, as well as in-depth interviews with specialists in mal de ojo, in-depth interviews with lay people who believe in this illness, and review of archival materials, this paper describes the contemporary explanatory model of mal de ojo and offers some hypotheses as to why beliefs in this illness, and other folk illnesses, persist

Las enfermedades populares en la cultura española actual : un estudio comparado sobre el mal de ojo

Cabe suponer que cuando se goza de acceso universal a la sanidad, como sucede en la España contemporánea, la creencia en enfermedades populares termina desapareciendo. Sin embargo, una investigación de campo, desarrollada en el Suroeste de Andalucía en la primavera de 2004, indica que aún resta en la generalidad de la población un considerable conocimiento de un cierto número de enfermedades populares, y en concreto de la denominada «Mal de ojo». A partir de los datos obtenidos mediante un grupo de discusión con mujeres que curan estas enfermedades, la realización de una serie de entrevistas a personas o bien muy familiarizadas con el Mal de ojo, o bien profanas en esta enfermedad pero que creen en ella, y finalmente una revisión de materiales de archivo. Este artículo describe un modelo actual explicativo del Mal de ojo y propone algunas hipótesis sobre la pervivencia de la creencia en esta y otras enfermedades populares.It might be assumed that in a situation of universal access to biomedical health care, as is the case in contemporary Spain, folk illness beliefs would have vanished. Field research conducted in the spring of 2004 in Andalusia showed considerable knowledge in the general population about a number of folk illnesses, including mal de ojo (evil eye). Based on a focus group conducted with traditional healers, as well as in-depth interviews with specialists in mal de ojo, in-depth interviews with lay people who believe in this illness, and review of archival materials, this paper describes the contemporary explanatory model of mal de ojo and offers some hypotheses as to why beliefs in this illness, and other folk illnesses, persist

Cancer outcomes among Parkinson's disease patients with leucine rich repeat kinase 2 mutations, idiopathic Parkinson's disease patients, and nonaffected controls

BACKGROUND: Increased cancer risk has been reported in Parkinson's disease (PD) patients carrying the leucine rich repeat kinase 2 (LRRK2) G2019S mutation (LRRK2-PD) in comparison with idiopathic PD (IPD). It is unclear whether the elevated risk would be maintained when compared with unaffected controls. METHODS: Cancer outcomes were compared among 257 LRRK2-PD patients, 712 IPD patients, and 218 controls recruited from 7 LRRK2 consortium centers using mixed-effects logistic regression. Data were then pooled with a previous study to examine cancer risk between 401 LRRK2-PD and 1946 IPD patients. RESULTS: Although cancer prevalence was similar among LRRK2-PD patients (32.3%), IPD patients (27.5%), and controls (27.5%; P = 0.33), LRRK2-PD had increased risks of leukemia (odds ratio [OR] = 4.55; 95% confidence interval [CI], 1.46-10.61) and skin cancer (OR = 1.61; 95% CI, 1.09-2.37). In the pooled analysis, LRRK2-PD patients had also elevated risks of leukemia (OR = 9.84; 95% CI, 2.15-44.94) and colon cancer (OR = 2.34; 95% CI, 1.15-4.74) when compared with IPD patients. CONCLUSIONS: The increased risks of leukemia as well as skin and colon cancers among LRRK2-PD patients suggest that LRRK2 mutations heighten risks of certain cancers. © 2019 International Parkinson and Movement Disorder Society

The prevalence and experience of Australian naturopaths and Western herbalists working within community pharmacies

<p>Abstract</p> <p>Background</p> <p>Naturopaths and Western herbal medicine (WHM) practitioners were surveyed to identify their extent, experience and roles within the community pharmacy setting and to explore their attitudes to integration of complementary medicine (CM) practitioners within the pharmacy setting.</p> <p>Method</p> <p>Practising naturopaths and WHM practitioners were invited to participate in an anonymous, self-administered, on-line survey. Participants were recruited using the mailing lists and websites of CM manufacturers and professional associations.</p> <p>Results</p> <p>479 practitioners participated. 24% of respondents (n = 111) reported they had worked in community pharmacy, three-quarters for less than 5 years. Whilst in this role 74% conducted specialist CMs sales, 62% short customer consultations, 52% long consultations in a private room and 51% staff education. This was generally described as a positive learning experience and many appreciated the opportunity to utilise their specialist knowledge in the service of both customers and pharmacy staff. 14% (n = 15) did not enjoy the experience of working in pharmacy at all and suggested pharmacist attitude largely influenced whether the experience was positive or not. Few practitioners were satisfied with the remuneration received. 44% of the total sample provided comment on the issue of integration into pharmacy, with the main concern being the perceived incommensurate paradigms of practice between pharmacy and naturopathy. Of the total sample, 38% reported that they would consider working as a practitioner in retail pharmacy in future.</p> <p>Conclusions</p> <p>The level of integration of CM into pharmacy is extending beyond the mere stocking of supplements. Naturopaths and Western Herbalists are becoming utilised in pharmacies</p